Table 1 Pregabalin and duloxetine drug-drug interactions

Pregabalin

Major

Reduced pregabalin effectiveness

naproxen, ketorolac

Contraindicated

CNS toxicity or serotonin syndrome

isocarboxazid, linezolid, procarbazine, rasagiline, selegiline, tranylcypromine

Increased serum concentrations of interacting drug and risk of cardiac arrhythmia

thioridazine

Increased risk of extrapyramidal reactions or neuroleptic malignant syndrome

metoclopramide

Increased risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions

methylene blue

Major

Increased interacting drug plasma level and Increased risk of QT prolongation

clozapine

Increased risk of bleeding

antiplatelet agents, escitalopram

Increased risk of serotonin syndrome

almotriptan, citalopram, cyclobenzaprine, desvenlafaxine, dextromethorphan, eletriptan, fluoxetine, fluvoxamine, frovatriptan, hydroxytryptophan, lithium, lorcaserin, methadone, milnacipran, naratriptan, paroxetine, rizatriptan, sertraline, sumatriptan, tapentadol, tramadol, trazodone, tryptophan, venlafaxine, zolmitriptan

Increased risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions

vilazodone

Increased serum concentrations of interacting drugs and an Increased risk of cardiotoxicity

class 1C antiarrhythmic agents

Moderate

decreased plasma concentrations of the active metabolites of interacting drug

tamoxifen

Increased duloxetine serum concentrations and risk of adverse effects

ciprofloxacin, clobazam, enoxacin, mirabegron, quinidine

Increased exposere to interacting drug and potential toxicity

phenothiazines, tamsulosin, tricyclic antidepressants

Increased risk of bleeding

acenocoumarol, dabigatran, dalteparin, danaparoid, desirudin, enoxaparin, fondaparinux, nonsteroidal anti-inflammatory agents, phenindione, phenprocoumon, tinzaparin, warfarin